Depression and epilepsy, pain and psychogenic non-epileptic seizures

Clinical and therapeutic perspectives

Andres M. Kanner, Steven C. Schachter, John J. Barry, Dale C. Hersdorffer, Marco Mula, Michael Trimble, Bruce Hermann, Alan E. Ettinger, David Dunn, Rochelle Caplan, Philippe Ryvlin, Frank Gilliam

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The clinical manifestations of depression in people with epilepsy (PWE) are pleomorphic, often associated with anxiety symptoms and anxiety disorders. The ongoing debate of whether the clinical presentation of depression in PWE is unique to this neurologic disorder is reviewed. Comorbid depression can impact the recruitment of PWE for pharmacologic trials with antiepileptic drugs (AEDs). Yet, the impact of depression on the response of the seizure disorder to pharmacotherapy with AEDs and its impact on worse adverse events may bias the interpretation of the trial findings, particularly when depressed patients are included in the AED trials. PWE have a greater suicidal risk than the general population. This risk is mediated by multiple factors, and recent data from the FDA have imputed a potential pathogenic role to all AEDs. The recognition of patients at risk is reviewed. Yet, the validity of the FDA data has been questioned, and the status of this controversial question is analyzed. As in the case of epilepsy, depression and pain syndromes have a relatively high comorbidity. The negative impact of depression on pain is reminiscent of that of depression in PWE; furthermore, the high comorbidity may be also associated with the existence of common pathogenic mechanisms. Neurologists and in particular, epileptologists establish the diagnosis of psychogenic non-epileptic seizures (PNES) in whom a comorbid depressive disorder is very often identified. The role of depression in the course of PNES and its treatment are discussed. Scarce data are available on the treatment of depression in PWE. Thus, clinicians have had to adopt data from patients with primary depressive disorders. We outline a consensus strategy on the identification and treatment of depressive disorders in adult and pediatric patients with epilepsy.

Original languageEnglish (US)
Pages (from-to)169-181
Number of pages13
JournalEpilepsy and Behavior
Volume24
Issue number2
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Epilepsy
Seizures
Depression
Pain
Anticonvulsants
Depressive Disorder
Therapeutics
Comorbidity
Nervous System Diseases
Anxiety Disorders
Consensus
Anxiety
Pediatrics
Drug Therapy
Population

Keywords

  • Major depressive episodes
  • Pain
  • Peri-ictal depressive episodes
  • Psychogenic non-epileptic seizures
  • Selective serotonin-reuptake inhibitors
  • Serotonin receptors
  • Suicidality

ASJC Scopus subject areas

  • Clinical Neurology
  • Behavioral Neuroscience
  • Neurology

Cite this

Kanner, A. M., Schachter, S. C., Barry, J. J., Hersdorffer, D. C., Mula, M., Trimble, M., ... Gilliam, F. (2012). Depression and epilepsy, pain and psychogenic non-epileptic seizures: Clinical and therapeutic perspectives. Epilepsy and Behavior, 24(2), 169-181. https://doi.org/10.1016/j.yebeh.2012.01.008

Depression and epilepsy, pain and psychogenic non-epileptic seizures : Clinical and therapeutic perspectives. / Kanner, Andres M.; Schachter, Steven C.; Barry, John J.; Hersdorffer, Dale C.; Mula, Marco; Trimble, Michael; Hermann, Bruce; Ettinger, Alan E.; Dunn, David; Caplan, Rochelle; Ryvlin, Philippe; Gilliam, Frank.

In: Epilepsy and Behavior, Vol. 24, No. 2, 06.2012, p. 169-181.

Research output: Contribution to journalArticle

Kanner, AM, Schachter, SC, Barry, JJ, Hersdorffer, DC, Mula, M, Trimble, M, Hermann, B, Ettinger, AE, Dunn, D, Caplan, R, Ryvlin, P & Gilliam, F 2012, 'Depression and epilepsy, pain and psychogenic non-epileptic seizures: Clinical and therapeutic perspectives', Epilepsy and Behavior, vol. 24, no. 2, pp. 169-181. https://doi.org/10.1016/j.yebeh.2012.01.008
Kanner, Andres M. ; Schachter, Steven C. ; Barry, John J. ; Hersdorffer, Dale C. ; Mula, Marco ; Trimble, Michael ; Hermann, Bruce ; Ettinger, Alan E. ; Dunn, David ; Caplan, Rochelle ; Ryvlin, Philippe ; Gilliam, Frank. / Depression and epilepsy, pain and psychogenic non-epileptic seizures : Clinical and therapeutic perspectives. In: Epilepsy and Behavior. 2012 ; Vol. 24, No. 2. pp. 169-181.
@article{70d23460a8dc4f2c80995083bbd9898c,
title = "Depression and epilepsy, pain and psychogenic non-epileptic seizures: Clinical and therapeutic perspectives",
abstract = "The clinical manifestations of depression in people with epilepsy (PWE) are pleomorphic, often associated with anxiety symptoms and anxiety disorders. The ongoing debate of whether the clinical presentation of depression in PWE is unique to this neurologic disorder is reviewed. Comorbid depression can impact the recruitment of PWE for pharmacologic trials with antiepileptic drugs (AEDs). Yet, the impact of depression on the response of the seizure disorder to pharmacotherapy with AEDs and its impact on worse adverse events may bias the interpretation of the trial findings, particularly when depressed patients are included in the AED trials. PWE have a greater suicidal risk than the general population. This risk is mediated by multiple factors, and recent data from the FDA have imputed a potential pathogenic role to all AEDs. The recognition of patients at risk is reviewed. Yet, the validity of the FDA data has been questioned, and the status of this controversial question is analyzed. As in the case of epilepsy, depression and pain syndromes have a relatively high comorbidity. The negative impact of depression on pain is reminiscent of that of depression in PWE; furthermore, the high comorbidity may be also associated with the existence of common pathogenic mechanisms. Neurologists and in particular, epileptologists establish the diagnosis of psychogenic non-epileptic seizures (PNES) in whom a comorbid depressive disorder is very often identified. The role of depression in the course of PNES and its treatment are discussed. Scarce data are available on the treatment of depression in PWE. Thus, clinicians have had to adopt data from patients with primary depressive disorders. We outline a consensus strategy on the identification and treatment of depressive disorders in adult and pediatric patients with epilepsy.",
keywords = "Major depressive episodes, Pain, Peri-ictal depressive episodes, Psychogenic non-epileptic seizures, Selective serotonin-reuptake inhibitors, Serotonin receptors, Suicidality",
author = "Kanner, {Andres M.} and Schachter, {Steven C.} and Barry, {John J.} and Hersdorffer, {Dale C.} and Marco Mula and Michael Trimble and Bruce Hermann and Ettinger, {Alan E.} and David Dunn and Rochelle Caplan and Philippe Ryvlin and Frank Gilliam",
year = "2012",
month = "6",
doi = "10.1016/j.yebeh.2012.01.008",
language = "English (US)",
volume = "24",
pages = "169--181",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Depression and epilepsy, pain and psychogenic non-epileptic seizures

T2 - Clinical and therapeutic perspectives

AU - Kanner, Andres M.

AU - Schachter, Steven C.

AU - Barry, John J.

AU - Hersdorffer, Dale C.

AU - Mula, Marco

AU - Trimble, Michael

AU - Hermann, Bruce

AU - Ettinger, Alan E.

AU - Dunn, David

AU - Caplan, Rochelle

AU - Ryvlin, Philippe

AU - Gilliam, Frank

PY - 2012/6

Y1 - 2012/6

N2 - The clinical manifestations of depression in people with epilepsy (PWE) are pleomorphic, often associated with anxiety symptoms and anxiety disorders. The ongoing debate of whether the clinical presentation of depression in PWE is unique to this neurologic disorder is reviewed. Comorbid depression can impact the recruitment of PWE for pharmacologic trials with antiepileptic drugs (AEDs). Yet, the impact of depression on the response of the seizure disorder to pharmacotherapy with AEDs and its impact on worse adverse events may bias the interpretation of the trial findings, particularly when depressed patients are included in the AED trials. PWE have a greater suicidal risk than the general population. This risk is mediated by multiple factors, and recent data from the FDA have imputed a potential pathogenic role to all AEDs. The recognition of patients at risk is reviewed. Yet, the validity of the FDA data has been questioned, and the status of this controversial question is analyzed. As in the case of epilepsy, depression and pain syndromes have a relatively high comorbidity. The negative impact of depression on pain is reminiscent of that of depression in PWE; furthermore, the high comorbidity may be also associated with the existence of common pathogenic mechanisms. Neurologists and in particular, epileptologists establish the diagnosis of psychogenic non-epileptic seizures (PNES) in whom a comorbid depressive disorder is very often identified. The role of depression in the course of PNES and its treatment are discussed. Scarce data are available on the treatment of depression in PWE. Thus, clinicians have had to adopt data from patients with primary depressive disorders. We outline a consensus strategy on the identification and treatment of depressive disorders in adult and pediatric patients with epilepsy.

AB - The clinical manifestations of depression in people with epilepsy (PWE) are pleomorphic, often associated with anxiety symptoms and anxiety disorders. The ongoing debate of whether the clinical presentation of depression in PWE is unique to this neurologic disorder is reviewed. Comorbid depression can impact the recruitment of PWE for pharmacologic trials with antiepileptic drugs (AEDs). Yet, the impact of depression on the response of the seizure disorder to pharmacotherapy with AEDs and its impact on worse adverse events may bias the interpretation of the trial findings, particularly when depressed patients are included in the AED trials. PWE have a greater suicidal risk than the general population. This risk is mediated by multiple factors, and recent data from the FDA have imputed a potential pathogenic role to all AEDs. The recognition of patients at risk is reviewed. Yet, the validity of the FDA data has been questioned, and the status of this controversial question is analyzed. As in the case of epilepsy, depression and pain syndromes have a relatively high comorbidity. The negative impact of depression on pain is reminiscent of that of depression in PWE; furthermore, the high comorbidity may be also associated with the existence of common pathogenic mechanisms. Neurologists and in particular, epileptologists establish the diagnosis of psychogenic non-epileptic seizures (PNES) in whom a comorbid depressive disorder is very often identified. The role of depression in the course of PNES and its treatment are discussed. Scarce data are available on the treatment of depression in PWE. Thus, clinicians have had to adopt data from patients with primary depressive disorders. We outline a consensus strategy on the identification and treatment of depressive disorders in adult and pediatric patients with epilepsy.

KW - Major depressive episodes

KW - Pain

KW - Peri-ictal depressive episodes

KW - Psychogenic non-epileptic seizures

KW - Selective serotonin-reuptake inhibitors

KW - Serotonin receptors

KW - Suicidality

UR - http://www.scopus.com/inward/record.url?scp=84861372196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861372196&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2012.01.008

DO - 10.1016/j.yebeh.2012.01.008

M3 - Article

VL - 24

SP - 169

EP - 181

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

IS - 2

ER -